Searchable abstracts of presentations at key conferences in endocrinology

ea0021p112 | Clinical practice/governance and case reports | SFEBES2009

Somatostatin analogues as an alternative treatment for type 1 gastric endocrine tumour: case report

Santos Ana P , Martins Raquel G , Couto Joana , Barbosa Ana P , Abreu Nuno , Leca Luis , Torres Isabel

Introduction: Gastric endocrine tumors (GET) are rare. Type 1 tumors are non-functioning, almost exclusively benign lesions, usually presenting as multiple polyps, usually <1 cm in diameter, which arise from gastric enterochromaffin-like cells in response to chronically elevated gastrin, secondary to (auto-immune) atrophic fundic gastritis. These tumors were traditionally treated with total gastrectomy, like adenocarcinomas. Currently, surveillance or endoscopic treatment ...

ea0049ep146 | Endocrine tumours and neoplasia | ECE2017

Glucose metabolism abnormalities and insulin resistance are frequent in well diferentiated digestive NETs

Santos Ana P , Santos Ana C , Castro Clara , Raposo Luis , Torres Isabel , Henrique Rui , Monteiro Mariana P , Cardoso M Helena

Introduction: Incidence of Digestive NETs (DNETs) has increased in the last 40 years. Visceral obesity, metabolic syndrome (MetS) and insulin resistance (IR) have been associated with several types of cancer.Aim: To evaluate possible associations of obesity, hyperinsulinemia and IR with well-differentiated (WD) DNETs through a case control study.Materials and methods: Ninety-six patients with gastrointestinal (75.0%) and pNET (22.9...

ea0058oc5.1 | Oral Communications 5 | BSPED2018

Growth outcomes in adolescents and adults with Silver-Russell syndrome and the effects of childhood growth hormone treatment

Lokulo-Sodipe Oluwakemi , Canton Ana P M , Giabicani Eloise , Ferrand Nawfel , Child Jenny , Wakeling Emma L , Binder Gerhard , Netchine Irene , Mackay Deborah J G , Inskip Hazel M , Byrne Christopher D , Davies Justin H , Temple I Karen

Childhood short stature in Silver-Russell syndrome (SRS) is frequently treated with growth hormone (GH), however final height and long-term body mass index (BMI) data are limited.Objective: To assess height and BMI in older individuals with molecularly confirmed SRS and compare those previously treated with GH to those untreated.Methods: Growth data on individuals aged ≥13 years with SRS were evaluated from UK, French and Ger...

ea0063gp62 | Reproductive Axis | ECE2019

Hypothalamic miR-30 regulates puberty onset via repression of the puberty-suppressing factor, Mkrn3

Castellano Juan M , Heras Violeta , Sangiao-Alvarellos Susana , Manfredi-Lozano Maria , Sanchez-Tapia Maria J , Ruiz-Pino Francisco , Roa Juan , Lara-Chica Maribel , Morrugares-Carmona Rosario , Abreu Ana P , Belsham Denise , Vazquez Maria J , Calzado Marco A , Pinilla Leonor , Gaytan Francisco , Latronico Ana C , Kaiser Ursula B , Tena-Sempere Manuel

Mkrn3, the maternally imprinted gene encoding the makorin RING-finger protein-3, has recently emerged as putative pubertal repressor, as evidenced by central precocity caused by MKRN3 mutations in humans; yet, the molecular underpinnings of this key regulatory action remain largely unexplored. We report herein that the microRNA, miR-30, with three binding sites in a highly conserved region of its 3’-untranslated region (UTR), operates as repressor of Mkrn3 to control pube...